Bivalirudin: profile and news

The Medicines Company Announces Glenn Sblendorio to Be New Chief ...  06 Mar 2006
The Company markets Angiomax(R) (bivalirudin), an anti-clotting therapy approved in the US and other countries for use in patients undergoing coronary ... - Business Wire (press release),

The Medicines Company Reports Fourth Quarter and Full Year 2005 ...  Feb 15, 2006
Fourth quarter growth in underlying demand for Angiomax(R) (bivalirudin) enabled us to reach our revenue guidance, while also reducing wholesaler inventories ... - Genetic Engineering News,

Chairman of Cleveland Clinic Department of Cardiovascular Medicine ...  Feb 9, 2006
...recombinant t-PA, 2 different platelet glycoprotein IIb/IIIa inhibitors (abciximab and eptifibatide), and a new anticoagulant (bivalirudin) to patients with ... - International News Service,

Panacos Appoints Dr. John D. Richards Vice President ...  Feb 13, 2006
Since 1997 he has been a key member of The Medicines Company's management team that developed and launched Angiomax(R) (bivalirudin) in the US and oversaw the ... - Genetic Engineering News,

The Medicines Company to Announce Fourth Quarter and Full Year ...  Feb 8, 2006
The Company markets Angiomax(R)(bivalirudin), an anti-clotting therapy approved in the US and other countries for use in patients undergoing coronary ... - Genetic Engineering News,

News For Your Web Site  09 Feb 2006
The Company markets Angiomax(R)(bivalirudin), an anti-clotting therapy approved in the US and other countries for use in patients undergoing coronary ... - dBusinessNews Newark (press release),

Angiomax(R) (Bivalirudin) Recommended for Use in Percutaneous ...  Nov 15, 2005
Angiography and Interventions have jointly released updated guidelines recommending that the direct thrombin inhibitor Angiomax(R) (bivalirudin) be used in ... - Business Wire (press release),

Angiomax(R) (Bivalirudin) Recommended for Use in Percutaneous ...  Nov 15, 2005
Angiography and Interventions havejointly released updated guidelines recommending that the directthrombin inhibitor Angiomax(R) (bivalirudin) be used in ... - Finanzen.net,

FDA Approvals: Angiomax, Depakote ER, Hylenex  Dec 8, 2005
Dec. 8, 2005 — The US Food and Drug Administration (FDA) has approved bivalirudin injection for use in patients with or at risk of heparin-induced ... - Medscape (subscription)

The Medicines Company Completes Enrollment of 13,800-Patient ...  Dec 7, 2005
This randomized clinical trial is evaluating the direct thrombin inhibitor Angiomax(R) (bivalirudin) replacing heparins (unfractionated heparin or enoxaparin ... - Business Wire (press release),

Enrolment of 13,800 patients completed in global trial of Angiox® ...  Dec 7, 2005
This randomised clinical trial evaluates the thrombin-specific anticoagulant Angiox® (bivalirudin) replacing the combination of heparin (either unfractionated ... - Biotech Intelligence (press release),

TODAY ON PHARMALIVE.COM  Dec 1, 2005
The Medicines Company (NASDAQ: MDCO) today announced that the US Food and Drug Administration (FDA) approved the use of Angiomax(R) (bivalirudin) in patients ... - PharmaLive.com (press release),

The Addition of INTEGRILIN(R) (Eptifibatide) Injection Achieved ...  Nov 14, 2005
...to evaluate the effects of the addition of INTEGRILIN to an antithrombotic regimen of aspirin (325 mg) plus clopidogrel (600 mg) plus bivalirudin in elective ... - PR Newswire (press release),

Angiomax OK'd for HIT/HITTS  Dec 1, 2005
The drug maker said the Food and Drug Administration approved the use of Angiomax (bivalirudin) in patients with or at risk of heparin-induced thrombocytopenia ... - United Press International

The Medicines Company Lowers 2005 Guidance; Reports Preliminary ...  Oct 5, 2005
MDCO) today lowered its revenue guidance for 2005 based on less growth than previously forecast in end-user demand for Angiomax(R) (bivalirudin) and the ... - Genetic Engineering News,

New anticoagulant faces the challenge of bleeding in PCI  Sep 11, 2005
Angiox ™ (bivalirudin), however, enables significant reductions in post-PCI haemorrhagic complications while maintaining levels of efficacy in preventing ... - Medical News Today (press release),

The Medicines Company to Present at UBS Global Life Sciences ...  Sep 26, 2005
Clive Meanwell, Chairman and Chief Executive Officer, is expected to discuss company operations, Angiomax(R) (bivalirudin) marketing and development updates ... - dBusinessNews Newark (press release),

The Medicines Company Appoints Melvin Spigelman, MD to Board of ...  Sep 29, 2005
The Company markets Angiomax(R) (bivalirudin), an anti-clotting therapy approved in the US and other countries for use in patients undergoing coronary ... - Business Wire (press release),

Clopidogrel for Percutaneous Coronary Revascularization Time for ...  Sep 13, 2005
Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with ... - Journal of American Medical Association (subscription),

Direct Thrombin Inhibitors: Not Ready for Prime Time?  08 Sep 2005
In patients with unstable angina undergoing percutaneous coronary interventions, Angiomax (bivalirudin) may be superior to a combination of heparin and a ... - MedPage Today,

The Medicines Company to Present at Bear Stearns 18th Annual ...  Sep 7, 2005
Clive Meanwell, Chairman and Chief Executive Officer, is expected to discuss company operations, Angiomax(R) (bivalirudin) marketing, development updates for ... - Business Wire (press release),

Clopidogrel for Percutaneous Coronary Revascularization  Sep 4, 2005
Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with ... - Journal of American Medical Association (subscription),

The Medicines Company [MDCO] Chairman & CEO to Ring The NASDAQ ...  Aug 12, 2005
...of The Medicines Company (NASDAQ: MDCO), will preside over the opening bell to celebrate the sale of its 1 millionth vial of Angiomax® (bivalirudin) at its 5 ... - Market Wire (press release)

The Medicines Company to Present at Banc of America Conference  Jul 22, 2005
Clive Meanwell, Chairman and Chief Executive Officer, is expected to discuss company operations, Angiomax(R) (bivalirudin) marketing, development updates for ... - Genetic Engineering News

Increase in Diagnosed Events and Revascularization Procedures will ...  Aug 1, 2005
..."Key market drivers will include the increased use of Eli Lilly's ReoPro (abciximab) and The Medicines Company's Angiomax (bivalirudin) during percutaneous ... - Yahoo News (press release)

The Medicines Company to Announce Second Quarter 2005 Financial ...  Jul 13, 2005
The Company markets Angiomax(R) (bivalirudin), an anti-clotting therapy approved in the US and other countries for use in patients undergoing coronary ... - Business Wire (press release)

The Medicines Company Reports Second Quarter and First Half 2005 ...  Jul 20, 2005
PARSIPPANY, NJ--(BUSINESS WIRE)--July 20, 2005--The Medicines Company (NASDAQ: MDCO) today announced its financial results for the first half and second ... - Business Wire (press release) <**results**>

FDA Approves Expansion of the Medicines Company's Angiomax-R ...  Jun 15, 2005
Company (NASDAQ: MDCO) today announced that the US Food and Drug Administration (FDA) has approved new prescribing information for Angiomax(R) (bivalirudin). ... - Business Wire (press release)

Assessment of hemostatic activation during cardiopulmonary bypass ...  Jun 14, 2005
...(Email: koster{at}dhzb.de). OBJECTIVE: Bivalirudin has been successfully used as a replacement for heparin during on-pump coronary artery bypass grafting. ... - The Journal of Thoracic and Cardiovascular Surgery

FDA Approvals: Angiomax, Lyrica, Zmax  Jun 16, 2005
June 16, 2005 — The US Food and Drug Administration (FDA) has approved bivalirudin injection for use with aspirin and provisional glycoprotein inhibitors as ... - Medscape (subscription)

To Cath or Not to Cath That Is No Longer the Question  Jun 14, 2005
22 The role of direct thrombin inhibition by bivalirudin with or without Gp IIb/IIIa blockade is being tested in the ongoing Acute Catheterization and Urgent ... - Journal of American Medical Association (subscription),